Keywords: Amgen, Aranesp, Research, Side affects, Marketing practice, Kickbacks

Amgen’s Aranesp did not meet endpoints and increased risk of stroke; firm accused of kickbacks

Article | 02 November 2009

Print This

Leading US biotechnology firm Amgen suffered a double dose of bad news on October 30, when the firm revealed that its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in